With a renewed interest in vaccine research and development (R&D), stakeholders across the industry are rethinking their approach to the field. Biopharmaceutical companies have growing numbers of...
Stakeholders from across the industry, including biopharmaceutical companies, governments, and non-profit organizations, are rethinking their pandemic readiness in light of the COVID-19 pandemic,...
Authors: Dr. Ayaskant Pany, Sorika Van Niekerk, Johan Venter, Nuria Martinez-Alier, Viola-Marie RaubenheimerIncreased global travel means that infectious disease outbreaks are spreading faster and...
Authors: Dr. Ayaskant Pany and Sorika Van NiekerkRead somewhere recently: “What is the biggest constraint for tuberculosis (TB) clinical trials? RESOURCES!” This is so true not only in the...
Despite significant annual variation in research funding and global funding totals that fall far short of the field’s reported needs, the global market in tuberculosis (TB) diagnostics and treatments...
When most people think of emerging threats to public health, tuberculosis (TB) is unlikely to rise to the forefront of their minds. After all, TB has a long history and has been a well-known global...
Despite the fact that tuberculosis (TB) has been curable, it has become a global epidemic that impacts more people every year than HIV/AIDS. The millions of TB patients worldwide suffer from...